Intralesional antigen immunotherapy of Warts: Review Article | ||||
| Zagazig University Medical Journal | ||||
| Articles in Press, Accepted Manuscript, Available Online from 08 January 2024 | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/zumj.2024.257378.3065 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Waleed Mohamed Al-Balat; Eman Maher Abdel-Mawgoud Othman  ; Mai Ahmed Samir Awad
| ||||
| Dermatology, Venereology and Andrology Department, Faculty of Medicine, Zagazig University | ||||
| Abstract | ||||
| Common epidermal growths called warts are brought on by the human papillomavirus and can be extremely uncomfortable and embarrassing. Topical medications, cryotherapy, laser vaporization, and surgical excision are among the available treatment options today. While less severe techniques may result in lesion recurrence, many of these options are damaging and may cause scarring. Additionally, patients with a high number of warts cannot benefit from these local methods. Systemic treatments, including immunotherapy, have shown promise in treating multiple lesions by combining an immune system upregulatory response with a targeted strategy. Different antigens used in intralesional immunotherapy have demonstrated encouraging safety and efficacy in the treatment of warts. These therapies are believed to boost cell-mediated immunity (CMI), which in turn increases HPV recognition. We assess the effectiveness and side effects of intralesional immunotherapy in the management of warts in this review. With a comparatively higher efficacy of Candida antigen, intralesional antigen immunotherapy appears to be a viable, well-tolerated, and effective therapeutic approach for the treatment of multiple warts. | ||||
| Keywords | ||||
| Warts; antigen immunotherapy; Candida | ||||
|
Statistics Article View: 65 |
||||
